Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00346983
Recruitment Status : Terminated (Difficulty enrolling eligible subjects)
First Posted : July 4, 2006
Last Update Posted : May 12, 2008
Sponsor:
Collaborator:
Eyetech Pharmaceuticals
Information provided by:
Johns Hopkins University

Tracking Information
First Submitted Date  ICMJE June 29, 2006
First Posted Date  ICMJE July 4, 2006
Last Update Posted Date May 12, 2008
Study Start Date  ICMJE June 2006
Actual Primary Completion Date April 2007   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 19, 2007)
  • Proportion of subjects avoiding 15 letters (3 lines) of best-corrected distance visual acuity loss at 18 weeks after cataract surgery. Distribution of visual acuity changes at 18 weeks after cataract surgery [ Time Frame: 1 to 18 weeks post-cataract surgery ]
  • Distribution of absolute levels of distance visual acuity at 18 weeks after cataract surgery [ Time Frame: 1 to 18 weeks post-cataract surgery ]
  • Analysis of time to 15 letter improvement of best-corrected distance visual acuity through 18 weeks after cataract surgery using a 2-state stochastic model to account for events and recoveries from events [ Time Frame: 1 to 18 weeks post-cataract surgery ]
Original Primary Outcome Measures  ICMJE
 (submitted: June 29, 2006)
  • Proportion of subjects avoiding 15 letters (3 lines) of best-corrected distance visual acuity loss at 18 weeks after cataract surgery. Distribution of visual acuity changes at 18 weeks after cataract surgery
  • Distribution of absolute levels of distance visual acuity at 18 weeks after cataract surgery
  • Analysis of time to 15 letter improvement of best-corrected distance visual acuity through 18 weeks after cataract surgery using a 2-state stochastic model to account for events and recoveries from events
Change History Complete list of historical versions of study NCT00346983 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: November 19, 2007)
  • Analysis of improvement of fluorescein leakage seen on fluorescein angiography at 18 weeks after cataract surgery [ Time Frame: pre-cataract surgery to 18 weeks post-cataract surgery ]
  • Analysis of decrease in retinal thickness by OCT at 18 weeks after cataract surgery [ Time Frame: pre-cataract surgery to 18 weeks post-cataract surgery ]
  • Analysis of level of diabetic retinopathy using recognized photographic grading system at 18 weeks after cataract surgery [ Time Frame: pre-cataract surgery to 18 weeks post-cataract surgery ]
  • Additional changes 12 weeks after discontinuation of pegaptanib (6 months after study entry) [ Time Frame: pre-cataract surgery to 6 months post-cataract surgery ]
Original Secondary Outcome Measures  ICMJE
 (submitted: June 29, 2006)
  • Analysis of improvement of fluorescein leakage seen on fluorescein angiography at 18 weeks after cataract surgery
  • Analysis of decrease in retinal thickness by OCT at 18 weeks after cataract surgery
  • Analysis of level of diabetic retinopathy using recognized photographic grading system at 18 weeks after cataract surgery
  • Additional changes 12 weeks after discontinuation of pegaptanib (6 months after study entry)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
Official Title  ICMJE Pilot Study of the Effect of Pegaptanib Sodium to Prevent Worsening of Cystoid Macular Edema Following Cataract Surgery in Diabetics
Brief Summary This research is being conducted to look at the effects of an intraocular drug (pegaptanib, also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue in the back of the eye) that often occurs following cataract surgery in patients with diabetic eye disease. Swelling in the retina can lead to blurry vision, and Macugen may reduce this swelling. Eyedrops that decrease inflammation also may help to stop some of the swelling. We are testing this drug (pegaptanib) to see if it can decrease swelling in the retina and improve vision in patients with diabetes who are having cataract surgery.
Detailed Description

Macular edema occurs as a complication of cataract surgery in approximately 2% of all surgeries. In this condition, cystic, fluid-filled spaces develop in the outer plexiform layer of the retina resulting in a loss of vision. This condition is termed "Cystoid Macular Edema (CME)." In non-diabetics, the majority of such cases resolve spontaneously.

Diabetic macular edema (DME) is an important cause of visual disability among patients with diabetes. It is widely recognized that cataract surgery often triggers severe CME in patients with pre-existing DME. This exacerbation begins immediately following cataract surgery; and unlike in non-diabetics the edema is likely to be protracted and poorly responsive both to traditional treatments for CME (topical NSAIDS) and DME (laser photocoagulation). Fluorescein angiography, a photographic test that evaluates the blood circulation in the back of the eye, has demonstrated that both CME and DME are associated with increased permeability of retinal blood vessels.

The high rates and severity of post-cataract surgery CME in diabetic patients with DME render this population ideal for the study of potential agents to reduce the rate and severity of this condition (i.e., post-cataract surgery CME). Recent studies have shown that vascular endothelial growth factor (VEGF) plays a major role in vessel permeability. Pegaptanib (Macugen) is an FDA-approved drug for wet AMD. Pegaptanib is a selective VEGF antagonist that blocks the effects of VEGF; therefore pegaptanib might decrease vessel permeability and possibly decrease the incidence and severity of CME. We plan to conduct a controlled pilot study to investigate the effects of pegaptanib (up to 3 treatments of pegaptanib given prior to cataract surgery and as often as every 6 weeks for up to 12 weeks after cataract surgery) in diabetic patients with pre-existing DME who are undergoing cataract surgery and who are, therefore, at very high risk for development of CME. Should the pilot study indicate a potential benefit of pegaptanib in this setting, a larger, fully powered clinical trial will be proposed. An effective treatment or preventive measure for post-cataract surgery macular edema in patients with diabetic retinopathy would offer benefit to a large patient population nationally that is at high risk of vision loss.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Cystoid Macular Edema
Intervention  ICMJE
  • Drug: Pegaptanib sodium
    0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
    Other Name: Macugen
  • Drug: Control
    Sham injection, every 6 weeks, up to a total of 3 sham injections
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: Pegaptanib sodium
  • Placebo Comparator: B
    Intervention: Drug: Control
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: November 19, 2007)
4
Original Enrollment  ICMJE
 (submitted: June 29, 2006)
20
Actual Study Completion Date  ICMJE May 2007
Actual Primary Completion Date April 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adults (ages 18 years or older) with diabetes mellitus
  • Best corrected visual acuity worse than 20/40 but no worse than 20/800 in the study eye
  • Best corrected visual acuity better than or equal to 20/800 in the fellow eye
  • DME in the study eye (eye scheduled to undergo cataract surgery) as documented on OCT as a center point thickness of at least 250 microns no more than 3 weeks prior to cataract surgery
  • No prior laser photocoagulation in the study eye for at least 4 months prior to cataract surgery
  • Women of child-bearing potential who are interested in participating in this study will use two effective forms of contraception prior to initiation of pegaptanib and then throughout the remainder of the study. For women of childbearing potential, results from a urine pregnancy test will be obtained prior to each injection with pegaptanib. Urine samples will be disposed of after the test is performed.

Exclusion Criteria:

  • History of intravitreal steroid (triamcinolone) injection into the study eye within 4 months prior to cataract surgery
  • Macular edema due to non-diabetic etiologies such as vein occlusion
  • Retinal diseases that preclude evaluation of the macula for edema (e.g., macular hole)
  • Media opacity will not be an exclusion criterion provided that the investigator can assess the presence or absence of DME on OCT
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00346983
Other Study ID Numbers  ICMJE NA_00001385
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Oliver D. Schein, MD, Johns Hopkins University
Study Sponsor  ICMJE Johns Hopkins University
Collaborators  ICMJE Eyetech Pharmaceuticals
Investigators  ICMJE
Principal Investigator: Oliver D. Schein, MD, MPH, MBA Johns Hopkins University
PRS Account Johns Hopkins University
Verification Date May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP